Featured Tickers:
Sifting through countless of stocks in the Health Care Providers & Services industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Progyny, Inc., Henry Schein or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.
Read on to learn how Progyny, Inc., Henry Schein and Inc. compare based on key financial metrics to determine which better meets your investment needs.
About Progyny, Inc., Henry Schein and Inc.
Progyny, Inc., a benefits management company, provides fertility, family building, and women’s health benefits solutions in the United States. The company offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. It also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services. In addition, the company offers assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners, and alternate sites of care worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments. The company offers dental merchandise, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, and PPE products; dental equipment, such as dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as equipment repair; and branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, and vitamins. It also provides financial services on a nonrecourse basis, education services for practitioners, consulting, and other services; and consumable merchandise under its own brand. In addition, the company manufactures, markets, and sells dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products and other health care-related products and services. Further, it is involved in the development and distribution of practice management software, e-services, and other products to health care providers. The company serves customers in dental practices, laboratories, physician practices, and ambulatory surgery centers, as well as government, institutional health care clinics and other alternate care clinics. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.
Latest Health Care Providers & Services and Progyny, Inc., Henry Schein, Inc. Stock News
As of May 5, 2025, Progyny, Inc. had a $2.0 billion market capitalization, compared to the Health Care Providers & Services median of $1.1 million. Progyny, Inc.’s stock is up 35.4% in 2025, up 1.7% in the previous five trading days and down 27.53% in the past year.
Currently, Progyny, Inc.’s price-earnings ratio is 41.1. Progyny, Inc.’s trailing 12-month revenue is $1.2 billion with a 4.7% net profit margin. Year-over-year quarterly sales growth most recently was 10.6%. Analysts expect adjusted earnings to reach $1.604 per share for the current fiscal year. Progyny, Inc. does not currently pay a dividend.
As of May 5, 2025, Henry Schein, Inc. had a $8.1 billion market cap, putting it in the 78th percentile of all stocks. Henry Schein, Inc.’s stock is down 4.3% in 2025, up 0.1% in the previous five trading days and down 3.19% in the past year.
Currently, Henry Schein, Inc.’s price-earnings ratio is 20.7. Henry Schein, Inc.’s trailing 12-month revenue is $12.7 billion with a 3.2% net profit margin. Year-over-year quarterly sales growth most recently was -0.1%. Analysts expect adjusted earnings to reach $4.839 per share for the current fiscal year. Henry Schein, Inc. does not currently pay a dividend.
How We Compare Progyny, Inc., Henry Schein and Inc. Stock Grades
Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.
AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Progyny, Inc., Henry Schein and Inc.’s stock grades to see how they measure up against one another.
Learn more about A+ Investor here!
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions